Idiopathic Pulmonary Fibrosis Market Comprehensive Study by Leading Key Players: MediciNova, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Promedior, Inc., Merck & Co., Inc., Galapagos NV and more

The worldwide situation for idiopathic pulmonary fibrosis market is estimated at $ 1,161 million in 2016 and is expected to reach $ 356 million in 2023, an annual growth rate of 11.9% from 2017 to 2023. Perifennid occupies more than half of the entire market in 2016.

Idiopathic pulmonary fibrosis is a disease in which pulmonary tissue becomes thicker and harder over time, decreasing the ability of the tissue to carry oxygen. Market growth is expected due to the increase in the elderly population and the increase in patients with idiopathic pulmonary fibrosis. In addition, the growth of cigarette smoking increases the growth of the market. However, if treatment options that can completely cure the disease become unavailable, market growth will be limited.

Perifenidone is expected to dominate the market throughout the analysis period as it helps slow the scarring and preserve pulmonary function. Nintedanib is expected to register a high CAGR of 12.2% over the forecast period.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4407?utm_source=sy-Openpr

The major companies profiled in the report include
 MediciNova Inc.
 Boehringer Ingelheim
 F. Hoffmann-La Roche
 FibroGen Inc.
 Promedior Inc.
 Merck & Co. Inc.
 Galapagos NV
 Biogen
 Bristol-Myers Squibb Company
 Prometic Life Sciences Inc.
 Cipla Inc.

Buy Now (Data Pack Available with Discounted Price): @ https://www.alliedmarketresearch.com/checkout/368248?utm_source=sy-Openpr

Key Findings of the Idiopathic Pulmonary Fibrosis Market:
• Nintedanib is projected to grow at a CAGR of 12.2% during the forecast period.
• Pirfenidone accounted for more than half of the share of the global idiopathic pulmonary fibrosis market in 2016.
• France and Germany collectively contributed for more than one-third share of the European idiopathic pulmonary fibrosis market in 2016.
• Japan was the major shareholder in 2016, accounting for more than one-third share of the Asia-Pacific idiopathic pulmonary fibrosis market.
• Brazil is the major shareholder in 2016, accounting for nearly than one-fourth share of the LAMEA idiopathic pulmonary fibrosis market.

Asia-Pacific is projected to register the highest CAGR of 13.0% during the forecast period, owing to increase in incidence of population suffering from fibrotic disease and rise in ageing population. In addition, increase in healthcare expenditure offers a lucrative opportunity for the market growth.

Access Full Summery @ https://www.alliedmarketresearch.com/idiopathic-pulmonary-fibrosis-market?utm_source=sy-Openpr

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.